Earnings Call · Q1 FY2022·2022-05-04

Q1 22EPS -16.67%·Rev n/aQ4 21EPS -12.50%·Rev n/aQ3 21EPS +65.38%·Rev n/aQ2 21EPS +10.00%·Rev n/a⚠ consensus missing

ACADIA PHARMACEUTICALS INC ACAD

Mark Johnson — Vice President of Investor Relations

Stephen Davis — Chief Executive Officer

Brendan Teehan — Executive (likely Chief Commercial Officer or similar)

Serge Stankovic — Executive (likely Chief Medical Officer or similar)

Mark Schneyer — Executive (likely Chief Financial Officer or similar)

−5.3%1d on move date−1.8% vs SPY3d−17.6%5d−23.1%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ACAD calls or request research access.

More ACAD calls Browse calls Request research access